Trial Profile
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (Sine) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Selinexor (Primary) ; Azacitidine; Cytarabine; Decitabine; Hydroxycarbamide
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms SOPRA
- Sponsors Karyopharm Therapeutics
- 21 Jun 2020 Results assessing mutations associated with response to selinexor treatment presented at the 25th Congress of the European Haematology Association
- 16 May 2019 According to a Karyopharm Therapeutics Media Release, data from this trial will be presented at the upcoming European Hematology Association 2019 Annual Meeting.
- 16 Feb 2019 This trial has been completed in UK (Global end date: 2018-01-08).